Master Pharm SA said its first-quarter normalized net income came to 1.3 million zlotys, a rise of 56.3% from 800,630 zlotys in the year-earlier period.
Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.
The normalized profit margin fell to 10.9% from 11.3% in the year-earlier period.
Total revenue rose 61.0% on an annual basis to 11.5 million zlotys from 7.1 million zlotys, and total operating expenses rose 61.3% on an annual basis to 9.4 million zlotys from 5.9 million zlotys.
Reported net income increased 28.8% year over year to 1.3 million zlotys, or 7 groszy per share, from 1.0 million zlotys.
As of May 16, US$1 was equivalent to 3.85 zlotys.